-Sapirstein to Present Company Overview-
PRINCETON, N.J. and SAN DIEGO, Oct. 23 /PRNewswire/ -- Tobira Therapeutics, Inc., a company focused on the development of medicines with novel mechanisms of actions for infectious diseases, today announced it will present a corporate overview at the 2008 BIO Investor Forum. James Sapirstein, Chief Executive Officer and President will summarize the current status of the company including the status of TBR-652, a CCR5 antagonist in development for HIV-1 infection in adults. The presentation is scheduled for October 30, 2008 at 9:00 AM PST at The Palace Hotel, Two New Montgomery Street, San Francisco, Calif.
"We are delighted to share the growth Tobira Therapeutics, Inc. has experienced in the last 18 months at the BIO Investor Forum," said James Sapirstein. "This is a unique opportunity to review the great potential that we have to offer." Tobira Therapeutics is a clinical stage company and is not developing new technologies. The company is expanding its pipeline by being the partner of choice for suppliers, researchers, and alliance partners. A key component of Tobira's strategy is to acquire global rights to additional product candidates in infectious diseases, while continuing to develop and commercialize new products and line extensions.
The BIO Investor Forum will feature more than 190 public and venture-stage company presentations, in addition to drug and technology therapeutic workshops, breakout sessions, one-on-one investor meetings, and networking with industry executives and investors.
About Tobira Therapeutics, Inc.
Tobira Therapeutics is a private biopharmaceutical company which is
focused on developing and commercializing innovative antiviral compounds to
treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a
partner at the venture capital firm Domain Associates, to develop novel
treatments for HIV disease. Tobira has assembled a highly experienced
management team with decades of clinical and commercial development
experience specifically in HIV/AIDS drug development.
Tobira Therapeutics Inc.
Antoinette Bobbitt, Senior Director, Corporate and Business Development
firstname.lastname@example.org Tel: +1 609-897-1102
|SOURCE Tobira Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved